PMID- 27344184
OWN - NLM
STAT- MEDLINE
DCOM- 20180205
LR  - 20181202
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 7
IP  - 34
DP  - 2016 Aug 23
TI  - Prognostic value of amphiregulin and epiregulin mRNA expression in metastatic 
      colorectal cancer patients.
PG  - 55890-55899
LID - 10.18632/oncotarget.10151 [doi]
AB  - Epidermal growth factor receptor (EGFR) and its ligands amphiregulin (AREG) and 
      epiregulin (EREG) play a central role in the development of colorectal cancer, 
      but the prognostic values of AREG and EREG are controversial. We conducted a 
      meta-analysis of studies that investigated AREG and/or EREG mRNA levels in 
      primary tumors to determine their prognostic value in metastatic colorectal 
      cancer (mCRC). In addition, RAS status was assessed. Relevant articles were 
      identified by searching the EMBASE, PubMed, and Cochrane Library databases. 
      Hazard ratios (HR) with 95% confidence intervals (CIs) were calculated using a 
      random-effects model. Nine studies involving 2167 patients were included in this 
      meta-analysis. High AREG expression was associated with longer overall survival 
      (OS) and progression-free survival (PFS). High EREG expression was also 
      associated with prolonged OS and PFS. In RAS wild-type (WT) patients who received 
      anti-EGFR therapy, high AREG and EREG expression was associated with longer OS. 
      Our results indicate that high AREG and EREG mRNA expression are independent 
      favorable prognostic biomarkers in mCRC. The expression of these ligands should 
      be considered when evaluating prognoses in RAS-WT patients receiving anti-EGFR 
      therapy.
FAU - Jing, Chen
AU  - Jing C
AD  - Department of Medical Oncology, The First Affiliated Hospital of College of 
      Medicine, Zhejiang University, Hangzhou, Zhejiang, P.R. China.
FAU - Jin, Yang Han
AU  - Jin YH
AD  - Department of Pathology, The First Affiliated Hospital of College of Medicine, 
      Zhejiang University, Hangzhou, Zhejiang, P.R. China.
FAU - You, Zhai
AU  - You Z
AD  - Department of Pharmacy, The First Affiliated Hospital of College of Medicine, 
      Zhejiang University, Hangzhou, Zhejiang, P.R. China.
FAU - Qiong, Qian
AU  - Qiong Q
AD  - Department of Medical Oncology, The First Affiliated Hospital of College of 
      Medicine, Zhejiang University, Hangzhou, Zhejiang, P.R. China.
FAU - Jun, Zhou
AU  - Jun Z
AD  - Department of Pharmacy, The First Affiliated Hospital of College of Medicine, 
      Zhejiang University, Hangzhou, Zhejiang, P.R. China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (Amphiregulin)
RN  - 0 (Epiregulin)
RN  - 0 (RNA, Messenger)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Amphiregulin/*genetics
MH  - Colorectal Neoplasms/metabolism/*mortality/pathology
MH  - Epiregulin/*genetics
MH  - ErbB Receptors/antagonists & inhibitors
MH  - Genes, ras
MH  - Humans
MH  - Mutation
MH  - Neoplasm Metastasis
MH  - Prognosis
MH  - RNA, Messenger/*analysis
PMC - PMC5342459
OTO - NOTNLM
OT  - amphiregulin
OT  - epiregulin
OT  - meta-analysis
OT  - metastatic colorectal cancer
OT  - prognostic biomarker
COIS- CONFLICTS OF INTEREST There are no financial/commercial conflicts of interest 
      involving any of the authors of this study.
EDAT- 2016/06/28 06:00
MHDA- 2018/02/06 06:00
PMCR- 2016/08/23
CRDT- 2016/06/27 06:00
PHST- 2016/04/11 00:00 [received]
PHST- 2016/06/06 00:00 [accepted]
PHST- 2016/06/28 06:00 [pubmed]
PHST- 2018/02/06 06:00 [medline]
PHST- 2016/06/27 06:00 [entrez]
PHST- 2016/08/23 00:00 [pmc-release]
AID - 10151 [pii]
AID - 10.18632/oncotarget.10151 [doi]
PST - ppublish
SO  - Oncotarget. 2016 Aug 23;7(34):55890-55899. doi: 10.18632/oncotarget.10151.